|Bid||0.00 x 1100|
|Ask||0.00 x 2900|
|Day's Range||8.04 - 8.59|
|52 Week Range||4.35 - 10.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.75|
SAN FRANCISCO, June 13, 2018 /PRNewswire/ -- Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes, also called exonic copy number variants (CNVs), are present in a substantial number of patients and suggested that CNV testing should be universally used in clinical genetic testing. With few exceptions, these types of exonic CNVs are not typically detectable or reported from cytogenetic methods such as whole-genome chromosomal microarrays.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018 at 4:10 p.m. Central / 5:10 p.m. Eastern / 2:10 p.m. Pacific in Chicago. Invitae Corporation (NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices.
On a per-share basis, the San Francisco-based company said it had a loss of 66 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
-- Raising annual volume and revenue guidance -- -- Q1 2018 gross profit of $9.6M up from $1.0M in Q1 2017 -- -- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific -- ...
The Zacks Analyst Blog Highlights: Audiocodes, Farmland Partners, Invitae, Global Medical and Glu
Today we've highlighted five stocks that are currently trading for under $10 per share. All of these stocks currently sport a Zacks Rank #2 (Buy) or better, and the selected companies are showing signs of outpacing the market in the current calendar year.
Zacks.com featured highlights include: Del Taco, WellCare Health, Invitae, Visteon and Toll Brothers
"Our partnership with Invitae is important to advancing our clinical study objectives across our entire RNA-based platform," said Doug Ingram, Sarepta's President and CEO. DMD is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500 – 5,000 males worldwide and is caused by a change or mutation in the gene that encodes instructions for dystrophin.
NEW YORK, May 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LRAD ...
SAN FRANCISCO , May 3, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George , co-founder and chief executive officer of ...
SAN FRANCISCO, April 27, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that it is launching a new program with Biogen, a leading biotechnology company, to offer genetic testing at no charge to patients suspected of having or clinically diagnosed with spinal muscular atrophy (SMA), a rare, progressive, genetic, neuromuscular disease. The program, SMA Identified, is the latest addition to Invitae's network of partnerships that connect patients and clinicians to treatment and research. "We know that genetic testing has the ability to accelerate the diagnostic process, and an early diagnosis could lead to earlier intervention and better medical outcomes for patients with SMA," said Robert Nussbaum, MD, chief medical officer of Invitae.
SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that it will report its first quarter 2018 financial results on Wednesday, May 9, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 9158119. Invitae Corporation (NVTA) is a genetic testing and information company.
SAN FRANCISCO, March 28, 2018 /PRNewswire/ -- Invitae Corporation (NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million.
Invitae Corporation’s (NYSE:NVTA): Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in theRead More...
Gainers: AnaptysBio Inc (NASDAQ: ANAB ) shares are up 8 percent on news of positive top-line proof-of-concept data for ANB020 in peanut allergy patients. Sears Hometown and Outlet Stores Inc (NASDAQ: SHOS ...
SAN FRANCISCO, March 26, 2018 /PRNewswire/ -- Invitae Corporation (NVTA) today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.
SAN FRANCISCO, March 22, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetic information companies, today announced an expansion of its network of rare and ultra-rare patient registries in its Patient Insights NetworkTM (PIN) program to include five additional collaborations with leading advocacy groups across a variety of genetic conditions. The programs are designed to empower patients to be active participants in their networks and further expand Invitae's work to connect patients with rare genetic disorders to research, clinical trials and information on managing their condition. The first PIN to launch is led by No Stomach For Cancer, a leading research and advocacy organization focused on stomach cancer.